ABMTX
Latest round
- Series B
Last raised
- Jan 2022
Total raised
- $50M
Investors
- 13
About ABMTX
Based in Shanghai, China and established in 2016, ABMTX is medicine development company that focuses on small molecule tumor targeting drugs. The company's main business is research and development of small molecule drugs that can break through the blood-brain barrier. The company self-developed product such as BRAF inhibitor ABM-1310 for the treatment of various malignant tumors and brain metastases.S. clinical research of the BRAF inhibitor ABM-1310 and the development of multiple existing preclinical projects and improve the company's research and development platform for small molecule innovative drugs into the brain.
Who invested in ABMTX
13 investors across 3 rounds
See all investors in ABMTX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ABMTX
Who invested in ABMTX?
ABMTX has 13 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ABMTX raised?
ABMTX has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did ABMTX last raise money?
ABMTX's most recent round on record is a Series B, in Jan 2022.
What does ABMTX do?
Based in Shanghai, China and established in 2016, ABMTX is medicine development company that focuses on small molecule tumor targeting drugs.
Where is ABMTX headquartered?
ABMTX is headquartered in Shanghai, China.
Which VCs invest in companies like ABMTX?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at ABMTX's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like ABMTX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.